R&D News | pharmaphorum

News

BridgeBio rebounds on ATTR cardiomyopathy data

BridgeBio is getting ready to file for FDA approval of its acoramidis drug for transthyretin amyloidosis (ATTR) cardiomyopathy, armed with positive results in a phase 3 tr

News

Donanemab data an “important advance” in Alzheimer’s

The full data from the TRAILBLAZER-ALZ 2 trial of Eli Lilly’s amyloid drug donanemab has confirmed the top-line results reported in May, but also

News

Alnylam showcases long-acting amyloid drug at AAIC

With the first amyloid-targeting drug now approved for Alzheimer’s disease, Alnylam has presented preliminary clinical results with a new candidate that could potentially

News

Lilly bulks up in obesity with $1.93bn Versanis buy

Already developing a trio of incretin drugs for obesity, Eli Lilly has its sights set on a candidate with a different mechanism of action that it hopes to acquire via a $1

News

First Wave faces choppy waters with cystic fibrosis drug

First Wave BioPharma can’t seem to catch a break in its efforts to bring a new drug to market for pancreatic insufficiency problems that affect most patients with cystic f

News

Apogee Therapeutics upsizes its IPO to $300m

In a small sign of a possible improvement in the sluggish biotech initial public offering (IPO) market, Apogee Therapeutics has said it expects gross proceeds of $300 mill

BridgeBio rebounds on ATTR cardiomyopathy data

Donanemab data an “important advance” in Alzheimer’s

Alnylam showcases long-acting amyloid drug at AAIC

Lilly bulks up in obesity with $1.93bn Versanis buy

First Wave faces choppy waters with cystic fibrosis drug

Apogee Therapeutics upsizes its IPO to $300m

Inept digital interaction undermining pharma with clinicians

How to meet your physicians where they are online

News

Editor's Picks